Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

237P - Real-world outcomes of hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with high tumor mutational burden (hTMB) treated with immune checkpoint inhibitors (ICI)

Date

16 Sep 2021

Session

ePoster Display

Presenters

Saranya Chumsri

Citation

Annals of Oncology (2021) 32 (suppl_5): S457-S515. 10.1016/annonc/annonc689

Authors

S. Chumsri1, S. Sammons2, L. Alder2, E. Sokol3, N.A. Danziger4, K. Raskina4, A.B. Schrock5, J. Venstrom6, T. Snow7, E. Castellanos8, E. Ochuonyo9, J. Snider8, K. Mcgregor10

Author affiliations

  • 1 Hematology Oncology, Mayo Clinic, 32224 - Jacksonville/US
  • 2 Oncology, Duke University, 27710 - Durham/US
  • 3 Cancer Genomics Research, Foundation Medicine, Inc., Cambridge/US
  • 4 Pathology Department, Foundation Medicine, Inc, 02141 - Cambridge/US
  • 5 Clinical Development Medical Affairs, Foundation Medicine, 02210 - Boston/US
  • 6 Foundation Medicine, Foundation Medicine, Cambridge/US
  • 7 Flatiron Health, Flatiron Health, 10013 - New York/US
  • 8 Research Oncology, Flatiron Health Inc., 10013 - New York/US
  • 9 Research Oncology, Flatiron Health Inc. - East Coast, 10013 - New York/US
  • 10 Medical Affairs, Foundation Medicine, Inc, 02210 - Boston/US
More

Abstract 237P

Background

ICI showed benefit in PD-L1+ triple-negative BC and solid tumors with hTMB (≥ 10 mut/Mb). There is limited data on ICI treated HR+HER2- BC. Prior work showed that 7% of HR+HER2- BC has hTMB, with an enrichment in lobular carcinoma (15%) and most harboring APOBEC signature (70%). The purpose of this study was to describe real-world time-totreatment-discontinuation (rwTTD) for hTMB HR+HER2- mBC patients (pts) treated with ICI.

Methods

Pts with HR+HER2- mBC from the nationwide (US-based) de-identified Flatiron Health (FH)-Foundation Medicine (FMI) Clinico-Genomic database (CGDB) with genomic profiling by FMI between 01/2011 – 09/2020 and ICI initiation ≥ 6 months (mo) prior to cutoff date were eligible. rwTTD was measured as the difference between the last and first drug episode within a given line of treatment (LOT). LOTs were derived based on FH algorithms. The de-identified EHR data came from ∼280 US cancer clinics (∼800 sites of care). Eligible pts from Mayo Clinic and Duke University were HR+HER2- mBC pts with hTMB tested via FMI between 09/2013 – 07/2020. Clinical data were manually extracted. Similar rwTTD was measured within a given oncologist-defined LOT.

Results

Of 103 eligible pts in CGDB, 20/103 had hTMB. 5/20 pts had ≥ 6 mo on ICI; their TMB was between 16.3-255.8 mut/Mb. 1/5 received ICI with chemotherapy. At Mayo and Duke, there were 37 eligible pts, 8/37 started ICI ≥ 6 mo prior to cutoff date. 4/8 pts had ≥ 6 mo on therapy, their TMB was between 15-74 mut/Mb, and 3/4 had ICI with chemotherapy. Table: 237P

HR+ HER2- hTMB mBC pts who received ICI in Mayo/Duke and CGDB cohorts

Mayo/Duke (n=8) CGDB (n=20)
APOBEC 6 (75%) 13 (65%)
Median TMB (IQR) 32.5 (23.2, 47.5) 20.9 (13.8, 33.8)
ICI Monotherapy 2 (25%) 14 (70%)
ICI Line
1-2 3 (37.5%) 1 (5.0%)
3+ 5 (62.5%) 19 (95%)
ICI > 6 mo 4 (50.0%) 5 (25.0%)
Median TTD (mo, 95%CI) 5.8 (2-NA) 2.8 (1.4-NA)

Conclusions

All cohorts included a subset of pts with ≥ 6 mo of ICI treatment. These pts tended to have hTMB and several received ICI with chemotherapy. Further studies are needed to identify a subset of HR+HER2- pts who are more likely to have durable response to ICI.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

S. Chumsri: Non-Financial Interests, Institutional, Research Grant: Merck; Non-Financial Interests, Institutional, Research Grant: Pfizer. E. Sokol, N.A. Danziger, K. Raskina, K. Mcgregor: Financial Interests, Personal, Full or part-time Employment: Foundation Medicine. A.B. Schrock, J. Venstrom, T. Snow, E. Castellanos, E. Ochuonyo: J. Snider Financial Interests, Personal, Full or part-time Employment: Flatiron. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings